Main outcome measures (VISA-P and VAS during sports) at 6, 12 and 24 weeks in the glyceryl trinitrate (GTN) and placebo groups
| GTN (n=16) | Placebo (n=17) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (mean (SD)) | 6 weeks (mean (SD)) | 12 weeks (mean (SD)) | 24 weeks (mean (SD)) | Baseline (mean (SD)) | 6 weeks (mean (SD)) | 12 weeks (mean (SD)) | 24 weeks (mean (SD)) | Difference (95% CI) 6 weeks | Difference (95% CI) 12 weeks | Difference (95% CI) 24 weeks | |
| VISA score (0–100) | 63 (16.4) | 64 (21.8) | 73 (15.3) | 75 (16.2) | 67.8 (10.9) | 67.7 (15.6) | 73.7 (20.7) | 80.7 (22.1) | 1.1 (−10.5 to 12.7) | 4.2 (−7.9 to 16.2) | −1.2 (−12.5 to 10) |
| VAS score (0–10)* | 4.1 (2.9) | 5.9 (3.1) | 6.6 (2) | 6.6 (3) | 5.8 (3) | 5.4 (3.3) | 6.6 (3.7) | 7.8 (3.1) | 2.3 (−0.7 to 5.3) | 1.8 (−0.8 to 4.2) | 0.4 (−2 to 2.8) |
*0=worst pain ever, 10=no pain.
VAS, Visual Analogue Scores; VISA-P, Victorian Institute of Sports Assessment-Patella.